A5113241904- Prostate Cancer Treatment and Research
- Renal cell carcinoma treatment
- Estrogen and related hormone effects
- Hormonal and reproductive studies
- Cancer, Lipids, and Metabolism
- Medical Imaging and Pathology Studies
- Renal and related cancers
- Pediatric Urology and Nephrology Studies
- Hedgehog Signaling Pathway Studies
- Peptidase Inhibition and Analysis
- Genetic and Kidney Cyst Diseases
- Protein Degradation and Inhibitors
- Childhood Cancer Survivors' Quality of Life
- Kidney Stones and Urolithiasis Treatments
- Bladder and Urothelial Cancer Treatments
- Ureteral procedures and complications
- Prostate Cancer Diagnosis and Treatment
- Ophthalmology and Eye Disorders
- Sexual Differentiation and Disorders
- Neonatal Respiratory Health Research
- Congenital Diaphragmatic Hernia Studies
Urology San Antonio
2017-2025
The University of Texas Health Science Center at Houston
2020
The University of Texas Health Science Center at San Antonio
2017-2018
5011 Background: Patients with mCRPC inevitably develop resistance to available therapies, eg, novel hormonal agents (NHAs), and experience disease progression. Certain mutations that can in the ligand-binding domain (LBD; amino acids 671–920) of AR gene during treatment have been associated poor outcomes. ARV-766 is a novel, potent, orally administered PROTAC degrader targets wild-type clinically relevant LBD mutants, including most prevalent L702H, H875Y, T878A mutations. We report initial...
Androgen deprivation therapy (ADT), a cornerstone of prostate cancer treatment, is commonly co-prescribed as combination therapy. To better understand the safety and tolerability profile relugolix, an oral non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist, in with abiraterone acetate (abiraterone) apalutamide, phase I study was undertaken. This ongoing, 52-week, open-label, parallel cohort relugolix men metastatic castration-sensitive (mCSPC) or castration-resistant...
156 Background: Relugolix (REL) is the only oral androgen deprivation therapy (ADT) indicated for advanced prostate cancer (aPC). Combining ADT with receptor signaling inhibitors (ARSIs) has shown improved clinical outcomes in hormone-sensitive and castration-resistant PC. This study evaluated safety tolerability of REL ARSIs abiraterone (ABI) or apalutamide (APA). Methods: In this open-label, two-part study, patients (pts) aPC, including ADT-experienced, were treated 52 weeks (wks). Part 1,...
You have accessJournal of UrologyKidney Cancer: Ablative Therapy1 Apr 2017MP100-01 PARTIAL NEPHRECTOMY VERSUS CRYOABLATION OR RADIOFREQUENCY ABLATION FOR CLINICAL STAGE T1 RENAL MASSES: SYSTEMATIC REVIEW AND META-ANALYSIS OF MORE THAN 3900 PATIENTS J. Ricardo Rivero, Jose De La Cerda, Hanzhang Wang, Ann M. Farrell, Michael A. Liss, Ronald Rodriguez, and Dharam Kaushik RiveroJ. Rivero More articles by this author , CerdaJose Cerda WangHanzhang Wang FarrellAnn Farrell LissMichael Liss...
What is this summary about? Advanced prostate cancer a that began in the (a part of male body) and has spread to other parts body. This review two clinical research studies patients with advanced who were treated relugolix combination therapy. Relugolix medicine taken by mouth lowers sex hormone, called testosterone. sometimes combined medicines such as novel hormonal therapies (NHTs) or chemotherapy treat cancer. In one study, an NHT (abiraterone apalutamide). second (enzalutamide)...
TPS207 Background: Androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) analogs or receptor antagonists is a cornerstone of prostate cancer treatment. As disease progresses, agents complementary mechansims are co-prescribed ADT to suppress extra-testicular testosterone production block androgen receptors on cells. Relugolix (120 mg) an oral non-peptide GnRH antagonist approved in the US for treatment aPC. In phase 3 study, relugolix maintained suppression castration...